Disappointing Bydureon EXSCEL Outcomes Data May Raise Stakes For Victoza
AstraZeneca's EXSCEL study could have created confidence in a GLP-1 class-wide outcomes benefit, but instead it has raised questions about whether differences in trial results boil down to trial design.
You may also be interested in...
Scrip takes a trip back through the highs of drug development, looking at successes including positive cardiovascular outcomes studies for cholesterol drugs, advances in cancer and breakthroughs in hemophilia.
Novo Nordisk's ESC satellite symposium on heels of FDA approval of CV event prevention claim for Victoza highlights differences compared to Sanofi's competing Lyxumia, which failed an outcomes study.
Victoza is the only drug in the GLP-1 class in Europe to have a label that includes the prevention of CV events (and only the second antidiabetic after Boehringer Ingelheim/Lilly’s SGLT2 inhibitor Jardiance) which will help slow down market share loss to Lilly's Trulicity.